OrbiMed Asia GP IV, L.P. — SEC Form 4 filings

SEC reporting owner CIK 1966836. 2 Form 4 filings on record with FilingPulse; latest filed 2024-04-05.

Transaction summary — filings shown

Covers all 2 filings on record, filed 2024-01-31 to 2024-04-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ArriVent Biopharma, Inc. (AVBP)Director, 10% owner12 legs · 444,444 sh · $7,999,9928
Kinnate Biopharma Inc. (KNTE)Director, 10% owner15

Form 4 filings — OrbiMed Asia GP IV, L.P.

FiledFormIssuerReported transactionsSource
2024-04-054Kinnate Biopharma Inc. (KNTE)
jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital GP VIII LLC, OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC
Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000EDGAR
2024-01-314ArriVent Biopharma, Inc. (AVBP)
jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Advisors IV Ltd
Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 moreEDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1966836 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →